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Abstract 
We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 
mg/m2 due to progressing disease. The patient experienced good clinical response, but un-
fortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyc-
eridemia occurs in high incidence with bexarotene therapy, management recommendations 
are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combina-
tion with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was 
instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and to hold bexarotene for 2 
weeks. After the 2-week break, bexarotene was restarted at 150 mg/m2. 
 © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Bexarotene induces significant lipid abnormalities in most patients (increased triglycer-
ides and total cholesterol and decreased high-density lipoprotein) within the first 2–4 weeks 
[1]. The fasting lipid panel should be monitored at baseline, followed weekly until response 
to bexarotene is determined/stabilized, and then checked every 8 weeks [1]. Recommenda-
tions from the manufacturer are to reduce the dose, discontinue, and/or add antilipemic 
therapy [1]. In studies, HMG-CoA reductase inhibitors were used to manage lipids; gemfibro-
zil is not recommended due to its potential for drug interactions [2]. 
Case Report 
The patient was a 69-year-old female diagnosed with T2 N0 stage IB versus T2 N1 stage 
IIA cutaneous T-cell lymphoma diagnosed in July 2015. Imaging at this time showed cervical 
lymphadenopathy up to 1.5 cm, but no biopsies were obtained. With limited nodular skin 
lesions on the back of her neck, scalp, and trunk, she was originally treated with narrowband 
ultraviolet B phototherapy and topical steroids. In November of 2017, a new nodular skin 
biopsy showed progressive disease (stage IIB disease), and systemic therapy was discussed. 
Upon physical examination, a nodular rash on her neck, scalp, trunk, and extremities was the 
only abnormality. At the time, the patient was on the following medications: Acetaminophen 
500 mg every 6 h as needed for pain, betamethasone 0.05% lotion as directed, diphenhy-
dramine 25 mg as directed, hydrochlorothiazide 25 mg daily, hydroxyzine 10 mg daily, keto-
conazole 2% shampoo as directed, triamcinolone acetonide 0.1% cream as directed, and a 
daily multivitamin. Bexarotene was started on November 29, 2017, at 300 mg/m2 (body 
surface area 1.81 mg/m2) upon recommendation from Radiation Oncology. The baseline 
lipid panel was within normal limits. 
Two weeks after bexarotene therapy initiation; triglycerides were at 639 mg/dL, with 
total cholesterol at 208 mg/dL and high-density lipoprotein (HDL) at 18 mg/dL. Atorvastatin 
20 mg daily was added to the patient’s regimen after this initial lipid panel had been ob-
tained on December 13, 2017. Triglycerides continued to rise for the next 2 weeks (1,067 
mg/dL on December 20 and 1,202 mg/dL on December 27). Fenofibrate 120 mg daily was 
added, and atorvastatin increased to 80 mg daily on January 3, 2018. Bexarotene therapy 
was stopped on January 19, 2018, due to the rapid rise of triglycerides (peaked at 1,507 
mg/dL on January 17, 2018) with no response to lipid-lowering therapy. Just 5 days after 
halting bexarotene, her triglycerides decreased to 520 mg/dL, with total cholesterol at 294 
mg/dL and HDL at 13 mg/dL.  
Bexarotene was held for 2 weeks, but lipid-lowering therapy was continued throughout 
this “drug holiday” in hopes that it will begin to take effect. On January 31, 2018, triglycer-
ides decreased to 144 mg/dL, with total cholesterol at 196 mg/dL and HDL at 43 mg/dL. 
Bexarotene was restarted at 150 mg/m2. Over the course of 2 weeks, triglycerides increased 
to 575 mg/dL and HDL decreased to 8 mg/dL. The rise in lipids was not as dramatic as in the 
previous bexarotene trial, and the trend has since plateaued (Table 1). If the lipid panel 
worsens, therapy must be discontinued. The patient has had a very good clinical response to 
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bexarotene, as her skin rash has almost completely resolved. Her palpable lymphadenopathy 
has also resolved. 
Discussion 
Bexarotene is commonly classified as a rexinoid due to its selective activity at retinoid X 
receptors (RXRs) [3]. It can be used systemically in patients with cutaneous T-cell lympho-
ma, specifically when patients have extensive plaques and tumors refractory to skin-directed 
therapy [4]. It can also be given topically in patients with less severe and localized disease. 
The most common side effect noted is hypertriglyceridemia, which has been reported in up 
to ~80% of the patients [3]. There are no established guidelines for the prevention and 
management of bexarotene-induced hypertriglyceridemia, and most resources will just en-
courage cessation of therapy. 
The mechanism of the side effect is still poorly understood, but one logical hypothesis 
has been made in which RXRs and liver X receptors (LXRs) can form a permissive heterodi-
mer that can lead to increased plasma triglyceride levels [5]. RXRs are unique nuclear recep-
tors that can modulate transcription by forming homo- or heterodimers with other nuclear 
receptors such as LXRs [5]. This heterodimer formation is believed to be the only way that 
LXRs can increase plasma triglycerides, and this is only done when the RXR portion of the 
heterodimer is agonized [5]. Hypertriglyceridemia is recognized as an independent risk fac-
tor for cardiovascular disease, and the unnatural rapid onset of this hypertriglyceridemia 
that can occur (particularly in this case) is an extra cause for concern. Little to no research 
has been found to identify cardiovascular risk in the setting of bexarotene-induced hypertri-
glyceridemia. 
Although a lack of management recommendations was previously mentioned, a UK con-
sensus statement in the British Journal of Dermatology contained very detailed recommenda-
tions [2]. Prior to therapy, a low-fat diet should be counseled, along with a decrease in alco-
hol and vitamin A intake (the latter due to retinoid activation) [2]. Fenofibrate should be 
started well ahead of therapy regardless of lipid profile due to the 2–3 months it could take 
to determine clinical efficacy (at least 1–2 weeks prior to initiation of therapy) [2]. Statins 
should also be considered in combination. Bexarotene is metabolized by CYP3A4 (low-level 
interaction with atorvastatin), so rosuvastatin is the preferred statin in this situation [5]. The 
combination of fenofibrate and a statin can increase the risk of myalgia, so following creatine 
kinase levels may be beneficial [2]. During therapy, starting at 150 mg/m2 may be helpful, 
even if it is only half the labeled dose for this type of cancer [2]. Titrating up by 75 mg every 
2–4 weeks may help ease the patient into therapy, but the medication should be stopped if 
triglycerides exceed 1,000 mg/dL [2]. If the fibrate-statin combination therapy is not pro-
ducing enough lipid-lowering effect, niacin and/or ezetimibe can be considered [2]. Howev-
er, this would further increase the risk of myalgia. The patient should be familiar with the 
risk, and creatine kinase labs should be checked if this option is chosen [2]. It is important to 
note that ezetimibe only decreases lipids absorbed from diet, and the mechanism behind 
bexarotene-induced hypertriglyceridemia is not well enough understood to confirm that 
ezetimibe can be efficacious in this scenario. Fish oil can be considered, as it is usually men-
tioned in the setting of hypertriglyceridemia. 
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Although most cancers are not considered immediate and emergent conditions, with-
holding treatment just to wait for lipid-lowering therapy to kick in will likely not go over 
well with any cancer patient, especially a newly diagnosed patients. In this case particularly, 
it took approximately 1 month and a half for the patient’s triglyceride levels to triple (at the 
least – the first lipid panel was taken 2 weeks after initiation). To add to that phenomenon, it 
took just 5 days after therapy cessation to return down around to where it started. Lipid-
lowering therapy may not have had any effect on this patient. Fibrates and statins need 
weeks to months to determine clinical efficacy, and that time frame was not able to be 
properly identified. Given that the patient has now been on atorvastatin and fenofibrate for 
over 1 month, restarting at half-dose and titrating up may produce more favorable results in 
terms of reducing this prevalent adverse effect. 
In conclusion, bexarotene-induced hypertriglyceridemia is a legitimate concern in all pa-
tients initiating therapy with bexarotene, regardless of a history of elevated triglycerides. 
Proactivity in the management of this adverse effect due to the high prevalence may limit the 
extent of the elevation in lipids and may provide enough benefit to safely continue bexaro-
tene therapy.  
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Table 1. Patient fasting lipid panels 
             
             
 12/13 12/20 12/27 1/3 1/17 1/24 1/31 2/7 2/14 2/21 2/28 3/6 
             
             
Total cholesterol, mg/dL 208 0.235 0.262 0.341 0.280 294 196 169 173 221 191 225 
Triglycerides, mg/dL 639 1,067 1,202 1,332 1,507 520 144 347 575 555 439 539 
High-density lipoprotein, mg/dL 018 000.8 000.8 00.15 000.9 013 043 026 008 009 009 015 
             
             
 
 
 
